OncoMatch/Clinical Trials/NCT05720117
A Study of PYX-201 in Advanced Solid Tumors
Is NCT05720117 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PYX-201 for solid tumor.
Treatment: PYX-201 — The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage III, IV
locally advanced/metastatic HR+ and HER2- breast cancer ... TNBC ... HNSCC ... and other solid tumor types
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: extra domain B splice variant of fibronectin (EDB+FN) targeting treatments
Previously received extra domain B splice variant of fibronectin (EDB+FN) targeting treatments at any time prior to the start of PYX-201 treatment.
Cannot have received: systemic anticancer therapy
Exception: within 28 days or within 5 half-lives (whichever is shorter) prior to the start of study drug
Received systemic anticancer therapy within 28 days or within 5 half-lives (whichever is shorter) prior to the start of study drug.
Cannot have received: palliative radiation therapy
Exception: within 14 days prior to the start of study drug
Palliative radiation therapy within 14 days prior to the start of study drug.
Cannot have received: high-dose chemotherapy requiring stem cell rescue
Prior high-dose chemotherapy requiring stem cell rescue.
Cannot have received: solid organ or bone marrow progenitor cell transplantation
Prior solid organ or bone marrow progenitor cell transplantation.
Lab requirements
Blood counts
Adequate hematologic function.
Kidney function
Adequate renal function.
Liver function
Adequate hepatic function.
Cardiac function
Corrected QTcF <470 msec.
Adequate hematologic function. Adequate hepatic function. Adequate renal function. Corrected QTcF <470 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- HonorHealth Research Institute · Scottsdale, Arizona
- Ronald Reagan UCLA Medical Center · Los Angeles, California
- SCRI - HealthOne Denver · Denver, Colorado
- SCRI - Florida Cancer Specialists · Sarasota, Florida
- Winship Cancer Institute, Emory University · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify